Temporal and spatial variability of immunosuppressive therapies in transplant patients: An observational study in Italy

M. Marino, A. Rosa, Marco Finocchietti, A. Bellini, F. Poggi, M. Massari, S. Spila Alegiani, L. Masiero, A. Ricci, Gaia Bedeschi, F. Puoti, M. Cardillo, S. Pierobon, Maurizio Nordio, E. Ferroni, Martina Zanforlini, G. Piccolo, O. Leoni, Stefano Ledda, P. Carta, Donatella Garau, E. Lucenteforte, M. Davoli, A. Addis, V. Belleudi
{"title":"Temporal and spatial variability of immunosuppressive therapies in transplant patients: An observational study in Italy","authors":"M. Marino, A. Rosa, Marco Finocchietti, A. Bellini, F. Poggi, M. Massari, S. Spila Alegiani, L. Masiero, A. Ricci, Gaia Bedeschi, F. Puoti, M. Cardillo, S. Pierobon, Maurizio Nordio, E. Ferroni, Martina Zanforlini, G. Piccolo, O. Leoni, Stefano Ledda, P. Carta, Donatella Garau, E. Lucenteforte, M. Davoli, A. Addis, V. Belleudi","doi":"10.3389/frtra.2022.1060621","DOIUrl":null,"url":null,"abstract":"Background In immunosuppression after transplantation, several multi-drug approaches are used, involving calcineurin inhibitors (CNI: tacrolimus-TAC or cyclosporine-CsA), antimetabolites (antiMs), mammalian target of rapamycin inhibitors (mTORis), and corticosteroids. However, data on immunosuppressive therapy by organ and its space–time variability are lacking. Methods An Italian multicentre observational cohort study was conducted using health information systems. Patients with incident transplant during 2009–2019 and resident in four regions (Veneto, Lombardy, Lazio, and Sardinia) were enrolled. The post-transplant immunosuppressive regimen was evaluated by organ, region, and year. Results The most dispensed regimen was triple-drug therapy for the kidneys [tacrolimus (TAC) + antiM + corticosteroids = 41.5%] and heart [cyclosporin  + antiM + corticosteroids = 36.6%] and double-drug therapy for liver recipients (TAC + corticosteroids = 35.4%). Several differences between regions and years emerged with regard to agents and the number of drugs used. Conclusion A high heterogeneity in immunosuppressive therapy post-transplant was found. Further studies are needed in order to investigate the reasons for this variability and to evaluate the risk–benefit profile of treatment schemes adopted in clinical practice.","PeriodicalId":317938,"journal":{"name":"Frontiers in Transplantation","volume":"7 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frtra.2022.1060621","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background In immunosuppression after transplantation, several multi-drug approaches are used, involving calcineurin inhibitors (CNI: tacrolimus-TAC or cyclosporine-CsA), antimetabolites (antiMs), mammalian target of rapamycin inhibitors (mTORis), and corticosteroids. However, data on immunosuppressive therapy by organ and its space–time variability are lacking. Methods An Italian multicentre observational cohort study was conducted using health information systems. Patients with incident transplant during 2009–2019 and resident in four regions (Veneto, Lombardy, Lazio, and Sardinia) were enrolled. The post-transplant immunosuppressive regimen was evaluated by organ, region, and year. Results The most dispensed regimen was triple-drug therapy for the kidneys [tacrolimus (TAC) + antiM + corticosteroids = 41.5%] and heart [cyclosporin  + antiM + corticosteroids = 36.6%] and double-drug therapy for liver recipients (TAC + corticosteroids = 35.4%). Several differences between regions and years emerged with regard to agents and the number of drugs used. Conclusion A high heterogeneity in immunosuppressive therapy post-transplant was found. Further studies are needed in order to investigate the reasons for this variability and to evaluate the risk–benefit profile of treatment schemes adopted in clinical practice.
移植患者免疫抑制治疗的时空变异性:意大利的一项观察性研究
在移植后的免疫抑制中,使用了几种多药方法,包括钙调磷酸酶抑制剂(CNI:他克莫司- tac或环孢素- csa)、抗代谢物(antiMs)、哺乳动物雷帕霉素靶点抑制剂(mTORis)和皮质类固醇。然而,关于器官免疫抑制治疗及其时空变异性的数据缺乏。方法采用意大利卫生信息系统进行多中心观察队列研究。2009-2019年期间,居住在四个地区(威尼托、伦巴第、拉齐奥和撒丁岛)的意外移植患者被纳入研究。移植后免疫抑制方案按器官、地区和年份进行评估。结果配药最多的方案为肾脏(他克莫司(TAC) +抗m +糖皮质激素= 41.5%)和心脏(环孢素+抗m +糖皮质激素= 36.6%)三联药治疗,肝脏(TAC +糖皮质激素= 35.4%)双药治疗。不同地区和年份之间在药物作用和使用药物数量方面出现了一些差异。结论移植后免疫抑制治疗存在高度异质性。需要进一步的研究来调查这种差异的原因,并评估临床实践中采用的治疗方案的风险-收益概况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信